CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge

@article{Elia2007CD4CD25RT,
  title={CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge},
  author={L. Elia and L. Aurisicchio and A. Facciabene and P. Giannetti and G. Ciliberto and N. L. Monica and F. Palombo},
  journal={Cancer Gene Therapy},
  year={2007},
  volume={14},
  pages={201-210}
}
Cancer vaccines are a promising approach to treating tumors or preventing tumor relapse through induction of an immune response against tumor-associated antigens (TAA). One major obstacle to successful therapy is the immunological tolerance against self-antigens which limits an effective antitumor immune response. As a transient reduction of immunological tolerance may enable more effective vaccination against self-tumor antigens, we explored this hypothesis in a CEA tolerant animal model with… Expand
A Novel Mouse Model for Evaluation and Prediction of HLA-A2-restricted CEA Cancer Vaccine Responses
Virus‐based immunotherapy of cancer: what do we know and where are we going?
  • M. SØRensen, A. Thomsen
  • Biology, Medicine
  • APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • 2007
Forkhead box P3-positive regulatory T cells in immune surveillance and cancer
Viral vectors in cancer immunotherapy: which vector for which strategy?
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
...
1
2
3
4
...